These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 11425409)

  • 1. Too much, too little, or none at all: dealing with substandard and fake drugs.
    Wan Po AL
    Lancet; 2001 Jun; 357(9272):1904. PubMed ID: 11425409
    [No Abstract]   [Full Text] [Related]  

  • 2. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.
    Topol EJ;
    Lancet; 2001 Jun; 357(9272):1905-14. PubMed ID: 11425410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial.
    Lincoff AM; Califf RM; Van de Werf F; Willerson JT; White HD; Armstrong PW; Guetta V; Gibler WB; Hochman JS; Bode C; Vahanian A; Steg PG; Ardissino D; Savonitto S; Bar F; Sadowski Z; Betriu A; Booth JE; Wolski K; Waller M; Topol EJ;
    JAMA; 2002 Nov; 288(17):2130-5. PubMed ID: 12413372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycoprotein IIb/IIIa blockade and thrombolytics: early lessons from the SPEED and GUSTO IV trials.
    Califf RM
    Am Heart J; 1999 Jul; 138(1 Pt 2):S12-5. PubMed ID: 10385786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators.
    Antman EM; Gibson CM; de Lemos JA; Giugliano RP; McCabe CH; Coussement P; Menown I; Nienaber CA; Rehders TC; Frey MJ; Van der Wieken R; Andresen D; Scherer J; Anderson K; Van de Werf F; Braunwald E
    Eur Heart J; 2000 Dec; 21(23):1944-53. PubMed ID: 11071800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial.
    Ellis SG; Armstrong P; Betriu A; Brodie B; Herrmann H; Montalescot G; Neumann FJ; Smith JJ; Topol E;
    Am Heart J; 2004 Apr; 147(4):E16. PubMed ID: 15077099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [GPIIb/IIIa blockers for optimizing thrombolysis in acute myocardial infarct].
    Nordt TK; Peter K; Bode C
    Herz; 2001 Apr; 26 Suppl 1():42-5. PubMed ID: 11349626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [ASSENT III and GUSTO V: is it the end of combination therapy with GPIIb/IIIa blockers and thrombolytics in myocardial infarction?].
    Vahanian A
    Ann Cardiol Angeiol (Paris); 2002 Jan; 51(1):6-7. PubMed ID: 12471654
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial.
    Simoons ML;
    Lancet; 2001 Jun; 357(9272):1915-24. PubMed ID: 11425411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial.
    Gurm HS; Lincoff AM; Lee D; Tang WH; Jia G; Booth JE; Califf RM; Ohman EM; Van de Werf F; Armstrong PW; Guetta V; Wilcox R; Topol EJ;
    J Am Coll Cardiol; 2004 Feb; 43(4):542-8. PubMed ID: 14975461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of abciximab in the treatment of coronary artery disease.
    Gabriel HM; Oliveira EI
    Expert Opin Biol Ther; 2006 Sep; 6(9):935-42. PubMed ID: 16918260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14.
    Coulter SA; Cannon CP; Ault KA; Antman EM; Van de Werf F; Adgey AA; Gibson CM; Giugliano RP; Mascelli MA; Scherer J; Barnathan ES; Braunwald E; Kleiman NS
    Circulation; 2000 Jun; 101(23):2690-5. PubMed ID: 10851205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombin generation and fibrinolytic activities among patients receiving reduced-dose alteplase plus abciximab or undergoing direct angioplasty plus abciximab for acute myocardial infarction.
    Mak KH; Lee LH; Wong A; Chan C; Koh TH; Lau KW; Lim YL
    Am J Cardiol; 2002 Apr; 89(8):930-6. PubMed ID: 11950430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined glycoprotein IIb/IIIa receptor inhibition and low-dose fibrinolysis for peripheral arterial thrombosis.
    Rocha-Singh KJ; Trokey J
    Catheter Cardiovasc Interv; 2002 Apr; 55(4):457-60. PubMed ID: 11948891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective treatment with abciximab for consecutive bilateral middle cerebral artery occlusion.
    Puetz V; Weise M; von Kummer R; Gahn G
    Cerebrovasc Dis; 2006; 21(5-6):419-21. PubMed ID: 16549911
    [No Abstract]   [Full Text] [Related]  

  • 16. Benefical effects of reteplase in combination with abciximab: platelet/leukocyte interactions and coagulation system.
    Szabo S; Walter T; Etzel D; Ehlers R; Kazmaier S; Beyer ME; Hoffmeister HM
    Int J Clin Pharmacol Res; 2003; 23(2-3):37-40. PubMed ID: 15018016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral arteries: treatment with antibodies of platelet receptors and reteplase for thrombolysis--APART trial.
    Tepe G; Hopfenzitz C; Dietz K; Wiskirchen J; Heller S; Ouriel K; Ziemer G; Claussen CD; Duda SH
    Radiology; 2006 Jun; 239(3):892-900. PubMed ID: 16641342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intra-arterial reteplase and intravenous abciximab in patients with acute ischemic stroke: an open-label, dose-ranging, phase I study.
    Qureshi AI; Harris-Lane P; Kirmani JF; Janjua N; Divani AA; Mohammad YM; Suarez JI; Montgomery MO
    Neurosurgery; 2006 Oct; 59(4):789-96; discussion 796-7. PubMed ID: 16915119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy for acute myocardial infarction: fibrinolytic therapy and glycoprotein IIb/IIIa inhibition.
    Califf RM
    Am Heart J; 2000 Feb; 139(2 Pt 2):S33-7. PubMed ID: 10650314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycoprotein IIb/IIIa inhibitors, surgery and bleeding.
    Aylward P
    Aust N Z J Med; 1998 Oct; 28(5):583-4. PubMed ID: 9847944
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.